國立臺灣大學醫學院暨工學院醫學工程研究所

博士論文

Institute of Biomedical Engineering College of Medicine and College of Engineering National Taiwan University Doctoral Dissertation

慢性腎臟病人認知功能缺損

與海馬迴萎縮之關聯研究

The Association of Cognitive Impairment and Hippocampal Atrophy in Chronic Kidney Disease

張峻源

Chun-Yuan Chang 指導教授:林發暄 博士 Advisor: Fa-Hsuan Lin, Ph.D.

中華民國 107 年 4 月

April, 2018

序言

失智症是全球面對人口老化一項嚴重的課題,對國家社會乃至於家庭個人的 衝擊影響尤為深遠。在電機所時就對人腦神經影像有特別的興趣,博班時便選擇 在醫工所林發暄教授實驗室中進行失智症人腦影像的相關研究。過去文獻已經發 現慢性腎臟病人的認知功能缺損是比正常腎功能人來的顯著,本篇論文藉由核磁 共振人腦影像配合臨床腎功能及心智功能評估,分析影像與臨床症狀相關性。

這篇研究的完成首先要感謝台北榮總傅中玲教授的指導,從臨床收集到文章 寫作對我助益良多。林發暄指導教授,自我研究生時期選修其人腦映像方法,對 神經影像研究目的及方法給予我莫大的啟蒙。

感謝口試委員張楊全教授、郭文瑞教授以及吳文超教授在我論文口試時的指 導,以不同專業領域的觀點給予寶貴和實用的建議,使我的論文內容更為充實。

感謝Eva、義程,這幾年相關的程式及實驗設計跟問題,給我很多的協助。 已畢業的若寧,謝謝她在陽明MRI實驗室的幫忙。謝謝若芙,對統計分析方法給 我很多寶貴的意見。感謝實驗室大管家彥如,舉凡出國開會、實驗經驗申請等, 幫我大大減少行政上的繁瑣時間。還有許多實驗室來來往往的夥伴,kevin、僕 射、tasso等等,讓我在實驗室的生活裡留下豐富的回憶;感謝我醫院的同事: 林逸昇以及簡仲賢醫師,在我課業繁忙之餘能幫我分擔臨床的工作。

最後要感謝我體貼美麗的太太彥吟及可愛懂事的女兒淮柔,讓我在工作學 業兩忙之際,沒有後顧之憂,不僅放鬆了自己更是充滿甜美的記憶,成全我在過 不惑之年完成博士學位的心願,最後辛苦甜美的果實願與你們一起分享。

Ι

長久以來慢性腎臟病人的認知功能缺損已經廣為注意,也有不少文獻提及 但是腦部結構變化以及認知表現和腎臟功能的關聯則很少被提及,到本論文旨在 探討這三者之間的關聯性。本研究共納入了性別年齡相似的慢性腎臟病人(CKD) 實驗組及正常腎功能對照組,每位受試者皆有接受腎功能檢查、完整的神經心知 功能評估以及腦部核磁共振檢查(MRI),腦部影像資料藉由軟體 FreeSurfer 分析 可以獲得腦部結構的各項參數,並藉此與臨床腎功能與心智功能量表進行統計分 析,結果發現相較於對照組,實驗組(CKD)有較低的簡單心智功能評估分數 (Mini-Mental State Examination, MMSE),較小的腦部灰質體積、海馬迴大小及皮 質厚度。而估算腎絲球過濾率(eGFR)則與前述四項有明顯相關性,進一步校正干 擾因子(confounding factors)線性分析發現, eGFR 對於認知功能、灰質體積及 皮質厚度有明顯負相關。結論在本研究中發現腎功能缺損在心智認知功能以及大 腦結構之灰質體積,海馬迴體積以及皮質厚度有明顯相關。

關鍵字:慢性腎臟病,心血管疾病、認知、核磁共振影像、灰質體積、海馬迴、 皮質厚度

Π

ABSTRACT

Cognition impairment is well known in patients with chronic kidney disease (CKD) The relationship between brain structure and cognitive performance in CKD patients is still under investigation. The study aimed to quantitatively assessment the relationship between brain structure and cognitive performance in patients with CKD. Thirty-nine patients with CKD and thirty-nine age- and sex-matched control participants were recruited from a tertiary medical center. All participants underwent 3-T MRI scan neuropsychological assessments, and renal function tests. FreeSurfer software was used for imaging processing and analysis, including measurement of cortical thickness and gray matter (GM) and white matter volumes. As a result, compared with control subjects (73.1 \pm 7.5 years old), patients with CKD (76.4 \pm 8.4 years old) had significantly lower scores on the Mini-Mental State Examination, and forward digit span test (p < 0.01). Patients with CKD had smaller cerebral GM volume, hippocampus and decreased cortical thickness (p < 0.01) relative to the control group. Estimated glomerular filtration rate (eGFR) was correlated with cognitive performance, cortical thickness, GM volume, and hippocampal volume (p < p 0.001). Linear regression analysis revealed that eGFR and GM volume were

independently negatively associated with cognitive performance (p < 0.001), while

eGFR and age were negatively associated with cortical thinning and GM volume after

controlling for confounding factors. In conclusion, this study demonstrated that

impaired kidney function is associated not only with poor cognitive performance, but

also with small cerebral GM volume and reduced cortical thickness.

Index words: Chronic kidney disease, cardiovascular disease, cognition, magnetic resonance imaging, gray matter volume, Hippocampus, cortical thickness

T.	ABLI	E OF CONTENTS	調査
	序	言	I
	摘	要	u .
	AB	STRACT	ЛП
	LIS	ST OF FIGURES	VI
	LIS	ST OF TABLES	VII
1.	INTR	ODUCTION	1
2.	METI	HODS	2
	2.1	PARTICIPANTS	2
	2.2	DATA COLLECTION AND ASSESSMENTS	4
	2.2.1	Neuropsychological tests	4
	2.2.2	MRI data acquisition & Imaging processing	5
	2.2.3	Statistical analysis	8
3.	RESU	ILTS	9
	3.1	CHARACTERISTICS OF THE STUDY POPULATION	9
	3.2	RESULTS OF NEUROPSYCHOLOGICAL TESTING	
	3.3	HIPPOCAMPUS, GRAY MATTER VOLUME AND CORTICAL THICKNESS	
	3.4	CORRELATION ANALYSIS OF RENAL FUNCTION , COGNITION AND BRAIN MEASUREMEN	т16
4.	DISC	USSION	
5.	CONC	CLUSION	25
6.	REFE	RENCE	27
7.	APPE	ENDIX	

LIST OF FIGURES

LIST OF FIGURES	
FIGURE 1 THE AVERAGE BRAIN VOLUME IMAGE OF CONTROL SUBJECTS IS SHOWN ON A(CORONAL VIEW) AND	
B(AXIAL VIEW) WHEREAS THE BRAIN AVERAGE VOLUME IMAGE OF PATIENTS WITH CKD IS SHOWN ON C	
AND D. RED ARROW INDICATES THE HIPPOCAMPUS WHICH IS LOCATED ACCORDING TO TALAIRACH	
COORDINATES. DILATED VENTRICLE AND PERISYLVIAN SPACE AND REDUCED HIPPOCAMPAL VOLUME ARE	
NOTED IN CKD GROUP14	
FIGURE 2 MAPS IDENTIFYING REGIONS OF LESSER CORTICAL THICKNESS (HIGHLIGHTED) IN PATIENTS WITH CKD	
RELATIVE TO CONTROL SUBJECT	
FIGURE 3 CORRELATIONS AMONG EGFR, GRAY MATTER VOLUME, AND MMSE SCORE	

LIST OF TABLES

LIST OF TABLES
TABLE 1 DEMOGRAPHIC AND CLINICAL CHARACTERISTICS OF THE STUDY POPULATION
TABLE 2 NEUROPSYCHOLOGICAL TEST SCORES AND WHITE MATTER AND GRAY MATTER PARAMETERS
TABLE 3 ESTIMATES OF MULTIPLE LINEAR REGRESSION MODELS WITH NEUROPSYCHOLOGICAL TEST SCORES AND
BRAIN VOLUME PARAMETERS AS DEPENDENT VARIABLES AND AGE, EDUCATION AND CKD AS INDEPENDENT
VARIABLES, SHOWING EFFECTS BY STANDARDIZED COEFFICIENTS (BETA VALUE)
TABLE 4 RESULTS OF MULTIPLE LINEAR REGRESSION ANALYZING RENAL FUNCTION AND AGE AS PREDICTORS OF
BRAIN STRUCTURE

1. INTRODUCTION



progressive course and the risk of adverse outcomes. Cognitive impairment has long been recognized in patients with end-stage renal disease (ESRD). The prevalence of cognitive impairment in patients with kidney failure is approximately 30–60% (1-3), more than twice that found in an age-matched general population (4). The previous study demonstrated that middle-aged women with moderate CKD had significantly worse cognitive performance in delayed recalls and backward digit span tests than the control subjects (5). Other studies have also suggested that general cognitive dysfunction or specific cognitive impairments are already present in early stages of CKD (6, 7).

About one-third of middle-aged patients with CKD were found to have silent cerebral white matter (WM) lesions associated closely with vascular nephropathy (8). Some study showed that more white matter hyperintensity (WMH) were noted in the brains of patients with CKD (9) and a study conducted in Japan using indirect

semiquantitative measurement determined that the estimated glomerular filtration rate

(eGFR) was strongly associated with cerebral atrophy (10). Little is known about the

relationships between cognitive performance and brain structure features, as

characterized by detailed quantitative evaluation, in patients with CKD. Thus, the aim

of this study was to analyze the correlation between brain structure and cognitive

dysfunction by quantitative measurement of gray matter (GM), WM parameters, and the

cognitive performance in patients with CKD.

2. METHODS

2.1 Participants

We recruited patients with CKD and age- and sex-matched control participants from the nephrology and general outpatient clinics, respectively, of Taipei Veterans General Hospital (TVGH). The control subjects are those patients, or their spouses, who visit the clinics without memory complaints and with normal renal function. All patients with CKD have independent activities of daily living despite of various cognitive performances. Among these patients with CKD, 2 patients had stage 2 (mild), 18 patients had stage 3 (moderate), 11 patients had stage 4 (severe), and 8 patients had stage 5 (kidney failure) CKD. We classified subjects according to eGFR, determined using the abbreviated Modification of Diet in Renal Disease (MDRD) formula (11) :

 $eGFR = 186 \times (serum creatinine [mg/dL]^{-1.154}) \times age^{(-0.203)} \times (0.742 \text{ for women}).$

CKD was categorized according to the criteria of the U.S. National Kidney

Foundation Kidney Disease Outcomes Quality Initiative (12). Staging was based on

the presence of kidney damage and level of kidney function, defined by eGFR.

Kidney damage was defined as pathologic abnormalities or markers of damage,

including abnormalities detected by blood or urine test (e.g., hematuria, proteinuria, or pyuria) or imaging studies (e.g., renal cyst or collecting system abnormality), for more than 3 months. Stage 1 was defined as eGFR > 90, stage 2 (mild function reduction) as eGFR of 60–89 mL/min/1.73 m², stage 3 (moderate reduction) as eGFR of 30–59 mL/min/1.73 m², stage 4 (severe reduction) as eGFR of 15–29 mL/min/1.73 m²), and stage 5 (kidney failure) as eGFR < 15 mL/min/1.73 m².

Exclusion criteria were: current dialysis therapy, including peritoneal dialysis and hemodialysis; pregnancy or breast feeding; history of chemotherapy or radiation therapy for any cancer; psychiatric disorder; hearing or visual disability that could affect cognitive tests; clinical evidence of prior stroke; and prior diagnosis of dementia and abnormal activity of daily function.

2.2 Data collection and assessments

We recorded demographic and medical history data for each participant, and measured blood pressure, body weight, and height. The body mass index (BMI) was calculated as body weight divided by body height squared (kg/m²). All study participants underwent neuropsychological testing and brain magnetic resonance imaging (MRI). Blood samples were collected for the laboratory measurement of serum creatinine level, eGFR, and lipid profile.

2.2.1 Neuropsychological tests

The following tests were administered:

a. Mini-Mental State Examination (MMSE) (13): this 11-item questionnaire,

which evaluates subjects' memory, orientation, attention, calculation, and language, was used to screen for cognitive impairment. The highest possible score is 30 points, and lower scores reflect poorer cognition.

- b. Forward and backward digit span subtests of the Wechsler Adult Intelligence Scale-Revised (WAIS-R) (14): these tests require the participant to repeat digits in forward and reverse orders, respectively. The forward digit span test was used to evaluate attention and concentration, and the backward digit span test was used to evaluate attention and working memory.
- c. Verbal fluency test (15): this test requires the subject to name as many
 animals as possible in 1 min. The score is the number of different animals
 correctly named (one point for each correct response). This test can be used
 to evaluate language and executive function.

2.2.2 MRI data acquisition & Imaging processing

Brain MRI series were performed using a 3T MRI scanner (Discovery 750; General Electric, Milwaukee, PA, USA) with a T_1 -weighted pulse sequence. Imaging parameters were: repetition time/echo time/inversion time ([TR/TE/TI]) = 2,530/3.49/1,100 ms, flip angle = 7°, partition thickness = 1.33 mm, image matrix =

 256×256 , 128 partitions, and field of view = 21×21 cm. A fluid attenuation

inversion recovery (FLAIR) turbo spin-echo sequence was also performed using the following parameters: TR/TE/TI = 6,000/127.7/1,864 ms, slice thickness = 1 mm, image matrix = 256×256 , 180 slices, and field of view = 26×26 cm.

Structural T_1 MRI reconstruction was performed used FreeSurfer, version 5.1.0, which is a set of software tools for the study of neuroanatomy from brain MRI data (16-18). In the cortical surface stream, the tools construct models of the boundary between WM and GM, as well as the pial surface boundary between GM and cerebrospinal fluid (CSF). The GM/WM boundary was further processed to yield two triangulated mesh models with optimally 10242 vertices for each hemispheres (19-21). This cortical surface model was then used to facilitate visualization after "inflation"

(19, 20).

After reconstruction of these surfaces, an array of anatomical measures was generated, including cortical thickness, surface area, cortex curvature, surface normal direction at each point on the cortex, and volumes of major subcortical and ventricular structures. Procedures for the measurement of cortical thickness have been previously validated with histological analysis (22) and manual processing (23, 24). In addition, FreeSurfer defined a cortical surfaced-based atlas based on average folding patterns mapped to a

sphere. Surfaces from individuals were aligned with this atlas with a

high-dimensional nonlinear registration algorithm. The registration is based on aligning the cortical folding patterns and so directly aligns the anatomy instead of image intensities. The spherical atlas naturally forms a coordinate system in which point-to-point correspondence between subjects can be achieved. This coordinate system can then be used to morph between an individual subject and standard brain template and to create group maps (similar to how Talairach space is used for volumetric measurements (17)). Moreover, an array of noncortical structures, including the hippocampus, amygdala, lateral ventricles, and thalamus, were also automatically labeled. The total intracranial volume (TIV) is used to normalize volumes by simple division.

WMH was defined as hyperintense changes on intermediate-intensity FLAIR and T_2 -weighted images with no corresponding T_1 abnormality. WMH volumes were determined using FLAIR images and by automated WM lesion segmentation, the Lesion Segmentation Toolbox (LST)(25); it was an extension toolbox of Statistical

Parametric Mapping (SPM8), which is written in Matlab (MathWorks, Natick, Massachusetts). Previous study had showed good validity for determining WMH volume compared with subjective WM lesion rating scale(26).

2.2.3 Statistical analysis

All statistical analyses were carried out using SPSS (IBM SPSS statistics, version 22.0). Demographic and other health-related variables were compared between the moderate to severe CKD and control groups using *t*-tests or chi-squares tests, respectively. All results are presented as means ± standard deviation (SD), unless otherwise noted. Moreover, the brain volumetric measurements were corrected for age and neuropsychological tests were corrected for age and education by multiple linear regression. The t-statistics and associated p values were used in testing whether a given coefficient in regression equation is significantly different from zero. To test the hypothesis that CKD diagnosis was associated with neuropsychological test performance (outcome variable), Pearson correlation analyses and multivariate regression analyses adjusted for potential confounding variables, which were eGFR, age, education, diabetes, hypertensions, and hyperlipidemia, were performed. To

balance type I and type II errors in multiple comparisons, we defined a significance

level of p < 0.01. Statistical maps of the difference in cortical thickness were

thresholded at a false discovery rate (FDR) of 0.05(27).

3. RESULTS

3.1 Characteristics of the study population

In total, 39 (31M/8F) patients with CKD (mean age, 76.4 \pm 8.4 [range, 54–85] years) and 39 (32M/7F) subjects with normal renal function (mean age, 73.1 \pm 7.5 [range, 61–85] years) participated in this study. No difference in age, sex, education level, or BMI was observed between groups. Table 1 displays demographic and medical characteristics of the study sample. eGFR values were lower among patients with CKD than among control subjects (35.0 \pm 17.3 *vs*. 79.3 \pm 13.4, *p* < 0.001). The rates of diabetes, and dyslipidemia were higher among patients with CKD than among control subjects (*p* < 0.01).

9

Table 1 Demographic and clinical characteristics of the study population					
	CKD (<i>n</i> = 39)	Control (<i>n</i> = 39)	р		
Sex (male)	31 (79.4%)	32 (82.5%)	0.78		
Age (years)	76.4 ± 8.4 (54–85)	73.1 ± 7.5 (61–85)	0.07		
Education (years)	10.9 ± 4.9 (0–16)	12.9 ± 4.5 (0–16)	0.07		
Body mass index	24.6 ± 3.0	24.0 ± 2.7	0.52		
Diabetes mellitus	29 (74.4%)	8 (20.1%)	0.008		
Hypertension	34 (85.0%)	24 (61.5%)	0.02		
Dyslipidemia	24 (60.0%)	15 (38.5%)	0.035		
Serum creatinine (mg/dL)	2.50 ± 1.50	0.93 ± 0.16	<0.001		
eGFR (mL/min/1.73 m ²)	35.0 ± 17.3	79.3 ± 13.4	<0.001		
Mini-Mental Status	25.0 ± 4.2	29.4 ± 1.4	<0.001		
Examination	25.0 ± 4.2	26.4 ± 1.4	<0.001		

alini f +1 1 ak Table 1 D

Data are presented as n (%), mean \pm standard deviation, or mean \pm standard deviation

(range). CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate.

3.2 Results of neuropsychological testing



Table 2 shows neuropsychological test results. Compared with the control group,

patients with CKD had significantly lower scores on the MMSE (28.4 \pm 1.4 vs. 25.0 \pm

4.2) and forward digit span test (11.0 \pm 2.1 vs. 9.1 \pm 2.2; both corrected p < 0.01). No

difference in the backward digit span test and verbal fluency were observed between

groups after correcting for age and education by multiple linear regression model

(Table3).

Table 2 Neuropsychological test scores and white matter and gray matter parameters

	CKD	Control	р
	(<i>n</i> = 39)	(n = 39)	
Verbal fluency	11.7 ± 3.2	10.8 ± 3.1	0.04
Forward digit span	9.1 ± 2.2	11.0 ± 2.1	0.03
Backward digit span	5.8± 2.6	7.0 ± 2.1	0.35
WMH volume (mm ³)	18.8 ± 19.0	12.0 ± 15.1	0.09
Gray matter volume (10 ⁴ mm ³)	45.1 ± 4.3	48.1 ± 3.6	0.004

White matter volume (10 ⁴ mm ³)	34.7 ± 5.4	38.1 ± 4.4	0.007
Hippocampus (10 ³ mm ³)	6.7 ± 0.8	7.5 ± 0.8	<0.001
Total intracranial volume (10 ⁴ mm ³)*	146.0±17.4	149.9±14.3	0.29
Cortical thickness (mm)	2.49 ± 0.15	2.59 ± 0.12	<0.001**

CKD, chronic kidney disease; WMH, white matter hyperintensity. *estimated

total intracranial volume; ** Corrected p using FDR=0.05

Table 3. Estimates of multiple linear regression models with neuropsychological test scores and brain volume parameters as dependent variables and age, education and CKD as independent variables, showing effects by standardized coefficients (beta value)

	Variables control in the models				
Dependent variable	Age	CKD ^a	Education		
MMSE	-0.03	-0.42**	0.25		
Verbal fluency	-0.37 *	0.24	0.18		
Forward Digit span	-0.11	-0.35 *	0.15		
Backward Digit span	-0.21	-0.10	-0.41**		
WMH volume	0.19	0.15			
Gray matter volume	-0.19	-0.32*			
White matter volume	-0.12	-0.31 *			
Hippocampus volume	-0.30*	-0.38 **			
Total intracranial volume	0.09	-0.14			
Cortical thickness	-0.28*	-0.33 *			

CKD, Chronic kidney disease; MMSE, Mini-Mental State Examination; WMH, White matter hyperintensity; CKD^a, 0=normal control, 1=CKD; **P*<0.01; ***P*<0.0001

3.3 Hippocampus, Gray matter volume and cortical thickness

Brain morphometric values are presented in Table 2 .The effect of CKD status on brain volume after corrected for age by multiple linear regression are shown in Table 3. Detailed regression analyses are listed in supplemental table S1. Cerebral GM, WM and hippocampus volumes are smaller in patients with CKD than in control subjects by 6.2%, 8.9% and 10.7% respectively (p < 0.01) (Figure 1). There is no significant difference in WMH volume between two groups. Average cortical thickness was lower among patients with CKD than among control subjects (2.49 \pm $0.15 \text{ vs.} 2.59 \pm 0.12 \text{ mm}, p = 0.003$). Using an FDR of 0.05, we found that 2.7% and 3.5% of brain surface vertices in the right and left hemispheres (n = 10,242 each), respectively, were smaller in the CKD group than in the control group. Figure 2 shows the main differences in cortical thickness between two groups. There are in the bilateral occipito-temporal medial lingual gyri, left frontal pole, bilateral superior

temporal sulci, left calcarine sulci, left inferior temporal sulcus, right superior circular

insula and right parieto-occipital sulcus (Table S2).





Figure 1 The average brain volume image of control subjects is shown on A(coronal view) and B(axial view) whereas the brain average volume image of patients with CKD is shown on C and D. Red arrow indicates the hippocampus which is located according to Talairach coordinates. Dilated ventricle and perisylvian space and reduced hippocampal volume are noted in CKD group



Figure 2 Maps identifying regions of lesser cortical thickness (highlighted) in patients with CKD relative to control subjects. Main affected regions were the lateral temporal, orbital frontal, and occipital lobes. (A, C) lateral and medial sides of the left hemisphere, respectively; (B, D) lateral and medial sides of the right hemisphere, respectively. Scale for false discovery rate (FDR) *p* values is 0.01–0.0001. LH, left hemisphere; RH, right hemisphere



measurement

eGFR was moderately correlated with MMSE score, cortical thickness, and GM and hippocampal volumes (r = 0.48, 0.43, 0.35, and 0.37, respectively; all p < 0.001), but not with WM or WMH volume (r = 0.27 and -0.07, respectively; p = 0.02 and p=0.58)(Figure 3). In addition, MMSE score was correlated with GM and hipoccampal volumes (r = 0.42 and 0.31, respectively; both p < 0.001;).



Figure 3 Correlations among eGFR, gray matter volume, and MMSE score eGFR was correlated with brain structure measurement and cognitive

performance. (A-D) while cogntion was correlated with global and hippocampal

volume(E,F)

r = correlation coefficient. MMSE, Mini-Mental State Examination; eGFR,

estimated glomerular filtration rate (mL/min/1.73 m²)

A multiple linear regression model was created for each neuropsychological test to assess the significance of the effects of moderate to severe CKD diagnosis and brain morphometric measurement. GM volume, hippocampal volume and cortical thickness were set as dependent variables while independent variables were eGFR, age, years of education, diabetes, hypertension and dyslipidemia. Table 4 showed eGFR and age significantly predicted hippocampal volume, cortical thickness and GM volume (p < 0.01).

	eGFR	Age	Adjusted \mathbf{R}^2	р
	(Standardized	(Standardized		
	coefficient)	coefficient)		
Hippocampal volume	0.41	-0.35	0.30	0.001
Cortical thickness	0.36	-0.33	0.25	< 0.001
Gray matter volume	0.32	-0.22	0.15	0.001

Table 4 Results of multiple linear	regression analyzing	renal function a	nd age as
predictors of brain structure			

Data are R^2 = coefficient of determination. eGFR, estimated glomerular filtration

rate

4. **DISCUSSION**



In this study, we found that eGFR was moderately correlated with cognitive function, cortical thickness, and GM volume. Study participants with reduced kidney function, had impaired cognitive performance, less cortical thickness, and smaller hippocampal volume and GM volume than did subjects with normal renal function. In further regression analysis, we found that renal function and age were major contributing factors for cortical thickness, GM and hippocampal volume after controlling for confounding factors.

A few studies have reported brain atrophy and WMH burden in patients with CKD or renal failure (9, 10, 28-31). A meta-analysis of numerous structural and functional neuroimaging studies that examined children and adults with CKD identified several clear trends, including cerebral atrophy, WMH, cerebral infarction, microbleeding, and cerebral blood flow pattern with affective disorders (31). In the retrospective population-based Rotterdam Scan Study, subjects with low eGFR had smaller brain and deep WM volumes and more WMH (30). No close relationship was found between eGFR and GM or WM volume, which is not fully consistent with our results (30). The demographic characteristics of participants in the Rotterdam Scan Study differed from those in the present study subjects, such as lower percentage of diabetes and hypertension, and the higher ratio of male patients to female patients than those in the present population. Nevertheless, the Rotterdam Scan Study lacked neuropsychological assessment, which precluded correlation of brain measurements with cognitive performance. Most previous imaging analyses were focus on grading of WMH and detection of ischemic infarction, which were based on qualitative visual rating, rather than objective quantitative measurement. However, little about quantitative measurement of brain structure in patients with CKD was reported. Furthermore, the present study quantitatively showed the GM, WM and hippocampus volumes decreased by 6.2%, 8.9% and 10.7%, respectively, in patients with CKD compared with control subjects. The hippocampal volume seems to be more affected

by eGFR and age than global GM and WM volume.

In present study, significant cortical thinning in bilateral superior temporal sulci and medial lingual gyri was found in these patients with CKD and they showed lower global cognition scores and poorer performance in working memory (forward digit span) than those in the control group. In patients with mild cognitive impairment a or dementia, cortical thinning has been found in association with cardiovascular risk factors, such as hypertension and diabetes (32). However, eGFR and age were independently related to GM volume and cortical thickness in analyses controlling for the vascular component in the present study. The CKD group also had a significant reduction in hippocampal volume. Hippocampal atrophy has been shown to be an effective marker differentiating people with normal and impaired cognition, regardless of WMH and lacunar infarcts (33). Thus, renal function seems to be an independent factor affecting cortical atrophy and thinning *via* an uncertain mechanism rather than cerebrovascular risk factors. Nevertheless, the difference in WMH between patients with CKD and control subjects didn't reach significant level in this study. This result may be explained by the more frequent occurrence of WMH in patients with advanced CKD and those receiving hemodialysis, whereas about half of patients in our study had moderate CKD.

In line with previous studies (2, 5, 34), the present study also showed that

patients with CKD had poorer global cognitive function, executive function, verbal and working memory than the control subjects. A recent meta-analysis found that both cross-sectional and longitudinal studies have demonstrated a significantly increased risk of cognitive impairment in patients with CKD (35). Furthermore, another longitudinal cohort study conducted in Japan found that CKD was associated with the risk of dementia in patients with v independent of vascular components (36). These results are consistent with the hypothesis of a connection between renal impairment and dementia risk.

The close relationship between cardiovascular risk factors and dementia with small vessel disease is well established (37). Recently, CKD was found to be related to neurological disorders and this brain–renal connection is thought to involve small vessel disease in kidney and brain, based on hemodynamic similarities (38). The main pathologic vascular feature of CKD and albuminuria, implied impaired kidney vascular integrity, which might also be found in other organs with similar vascular bed. Recent study showed lower eGFR was independently associated with lower cerebral blood flow. The impaired cerebral autoregulation, probably leading to hypoperfusion, was thought to increased risk of dementia (39). Furthermore it has been suggested that various toxins have been involved in the pathogenesis of cognitive impairment in uremic patients(40). Oxidative radicals, elevated serum homocysteine level and inflammation have also been related to cognitive impairment in dialysis patients. These toxic substance could lead to vascular endothelial dysfunction and thus aggravate atherosclerosis and increase risk of dementia(41). These studies implied that impaired renal function, as measured by decreased eGFR, with alterations in water and electrolytes balance, accumulation of vasoactive species, and chronic inflammation is related to cerebral small vessel disease, independent of cardiovascular risk factors (30). Such findings are consistent with our study results: impaired eGFR is correlated with reduced GM volume and global cognitive performance, independent of other cardiovascular disease. In contrast, some study showed that mild CKD was associated with an increased risk of Alzheimer disease (AD) (36). The longitudinal BRain IN Kidney disease (BRINK) study found smaller GM volume in region of interests (ROIs) associated with both AD (tempo-parietal areas) and vascular cognitive impairment (VCI)(frontal lobes), worse cognition

function than patients without CKD(42, 43). Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS) reported both Alzheimer type and vascular pathology were found in most elder sample with cognitive decline by necropsy(44). Thus the possibilities of mixed AD and VCI in CKD group should be also taken into account.

The strengths of this study include the examination of patients with moderate CKD and the use of automated MRI analysis, which make it possible to accurately quantify cortical thinning and GM and WM atrophy and to investigate subcortical WM lesions. The associations between CKD and cognitive performance, cortical GM volume, cortical thickness, as well as eGFR were clearly demonstrated. To my knowledge, this study is the first study on cognitive impairment in patients with CKD based on comprehensive quantitative measurement of brain structure and renal function.

This study has some limitations. First, diabetes was more prevalent among patients with CKD than among the control subjects, reflecting a similar difference in the Taiwanese population (the prevalence of diabetes is about 15% in individuals with and 4% in those without CKD) (45). To eliminate the effect of this difference,

analysis with multiple linear regression model adjusted for age, education, diabetes. and other comorbidities was applied. Second, patients in the present study were recruited from a tertiary medical center, rather than from a community-based hospital, which may have led to selection bias. Third, smoking is indeed a major cardiovascular factor and it was not controlled in the present study. This might cause some bias. Forth, the present study did not perform CSF markers check-up and PET isotope study, the possibilities of prodrome of AD in CKD group cannot be excluded. Finally, though cortical thickness, GM volume, and MMSE score were lower in the CKD group than in the control subjects, the cause-effect relationships between renal function, brain morphometric features and cognitive performance remain uncertain because of the cross-sectional study design and lack of longitudinal follow-up.

5. Conclusion

In conclusion, the results of this study show that impaired kidney function is independently related to cerebral hippocampal volume, GM volume, cortical thickness, and cognitive performance after adjusting the confounding vascular risk factors. The mechanism of cognitive impairment in patients with CKD may not only be related to small vessel disease but also involved the neurodegenerative process. The results further emphasize the importance of identifying those with subclinical CKD, in whom impaired renal function might play a crucial role in cognitive decline and brain morphometric changes. These patients might benefit from early and appropriate therapy. Clinicians' monitoring of cognitive performance in patients with CKD using brain structure surveys is important. However, more studies are needed to investigate the extent to which any intervention can be beneficial.

6. Reference



- (1) SEHGAL AR, GREY SF, DEOREO PB, WHITEHOUSE PJ. Prevalence, recognition, and implications of mental impairment among hemodialysis patients. American Journal of Kidney Diseases 1997; 30: 41-9.
- KURELLA M, CHERTOW GM, LUAN J, YAFFE K. Cognitive impairment in chronic kidney disease. Journal of the American Geriatrics Society 2004; 52: 1863-9.
- (3) KURELLA M, LUAN J, YAFFE K, CHERTOW GM. Validation of the Kidney Disease Quality of Life (KDQOL) cognitive function subscale. Kidney international 2004; 66: 2361-7.
- (4) GRAHAM JE, ROCKWOOD K, BEATTIE BL, et al. Prevalence and severity of cognitive impairment with and without dementia in an elderly population. Lancet 1997; 349: 1793-6.
- (5) TSAI CF, WANG SJ, FUH JL. Moderate chronic kidney disease is associated with reduced cognitive performance in midlife women. Kidney international 2010; 78: 605-10.
- (6) KURELLA M, CHERTOW GM, FRIED LF, et al. Chronic kidney disease and cognitive impairment in the elderly: the health, aging, and body composition study. Journal of the American Society of Nephrology : JASN 2005; 16: 2127-33.
- (7) SELIGER SL, SISCOVICK DS, STEHMAN-BREEN CO, et al. Moderate renal impairment and risk of dementia among older adults: The cardiovascular health cognition study. Journal of the American Society of Nephrology 2004; 15: 1904-11.
- (8) MARTINEZ-VEA A, SALVADO E, BARDAJI A, et al. Silent cerebral white matter lesions and their relationship with vascular risk factors in middle-aged predialysis patients with CKD. American journal of kidney diseases : the official journal of the National Kidney Foundation 2006; 47: 241-50.
- (9) FAZEKAS G, FAZEKAS F, SCHMIDT R, KAPELLER P, OFFENBACHER H,

KREJS GJ. Brain MRI findings and cognitive impairment in patients undergoing chronic hemodialysis treatment. Journal of the neurological sciences 1995; 134: 83-8.

- (10) YAKUSHIJI Y, NANRI Y, HIROTSU T, et al. Marked cerebral atrophy is correlated with kidney dysfunction in nondisabled adults. Hypertension research : official journal of the Japanese Society of Hypertension 2010; 33: 1232-7.
- (11) LEVEY AS, BOSCH JP, LEWIS JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Ann Intern Med 1999; 130: 461-70.
- (12) NATIONAL KIDNEY F. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. American journal of kidney diseases : the official journal of the National Kidney Foundation 2002; 39: S1-266.
- (13) FOLSTEIN MF, FOLSTEIN SE, MCHUGH PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. Journal of psychiatric research 1975; 12: 189-98.
- (14) DOPPELT JE, WALLACE WL. Standardization of the Wechsler adult intelligence scale for older persons. Journal of abnormal psychology 1955; 51: 312-30.
- (15) HARRISON JE, BUXTON P, HUSAIN M, WISE R. Short test of semantic and phonological fluency: normal performance, validity and test-retest reliability. The British journal of clinical psychology / the British Psychological Society 2000; 39 (Pt 2): 181-91.
- (16) FISCHL B, SERENO MI, DALE AM. Cortical surface-based analysis II: Inflation, flattening, and a surface-based coordinate system. NeuroImage 1999; 9: 195-207.
- (17) FISCHL B, VAN DER KOUWE A, DESTRIEUX C, et al. Automatically parcellating the human cerebral cortex. Cereb Cortex 2004; 14: 11-22.
- (18) FISCHL B, SALAT DH, BUSA E, et al. Whole brain segmentation: Automated labeling of neuroanatomical structures in the human brain. Neuron 2002; 33: 341-55.
- (19) DALE AM, FISCHL B, SERENO MI. Cortical surface-based analysis. I.

Segmentation and surface reconstruction. Neuroimage 1999; 9: 179-94.

- (20) FISCHL B, SERENO M, DALE A. Cortical surface-based analysis. II: Inflation, flattening, and a surface-based coordinate system. Neuroimage 1999; 9: 195-207.
- (21) FISCHL B, LIU A, DALE AM. Automated manifold surgery: constructing geometrically accurate and topologically correct models of the human cerebral cortex. IEEE Trans Med Imaging 2001; 20: 70-80.
- (22) ROSAS HD, LIU AK, HERSCH S, et al. Regional and progressive thinning of the cortical ribbon in Huntington's disease. Neurology 2002; 58: 695-701.
- (23) KUPERBERG GR, BROOME MR, MCGUIRE PK, et al. Regionally localized thinning of the cerebral cortex in schizophrenia. Arch Gen Psychiat 2003; 60: 878-88.
- (24) FISCHL B, SALAT DH, VAN DER KOUWE AJW, et al. Sequence-independent segmentation of magnetic resonance images. Neuroimage 2004; 23: S69-S84.
- (25) SCHMIDT P, GASER C, ARSIC M, et al. An automated tool for detection of FLAIR-hyperintense white-matter lesions in Multiple Sclerosis. Neuroimage 2012; 59: 3774-83.
- (26) MALDJIAN JA, WHITLOW CT, SAHA BN, et al. Automated white matter total lesion volume segmentation in diabetes. AJNR American journal of neuroradiology 2013; 34: 2265-70.
- (27) GENOVESE CR, LAZAR NA, NICHOLS T. Thresholding of statistical maps in functional neuroimaging using the false discovery rate. Neuroimage 2002; 15: 870-8.
- (28) SAVAZZI GM, CUSMANO F, MUSINI S. Cerebral imaging changes in patients with chronic renal failure treated conservatively or in hemodialysis. Nephron 2001; 89: 31-6.
- (29) KHATRI M, WRIGHT CB, NICKOLAS TL, et al. Chronic kidney disease is associated with white matter hyperintensity volume - The Northern Manhattan Study (NOMAS). Stroke 2007; 38: 3121-6.
- (30) IKRAM MA, VERNOOIJ MW, HOFMAN A, NIESSEN WJ, VAN DER LUGT A, BRETELER MM. Kidney function is related to cerebral small vessel disease. Stroke 2008; 39: 55-61.

- (31) MOODALBAIL DG, REISER KA, DETRE JA, et al. Systematic Review of Structural and Functional Neuroimaging Findings in Children and Adults with CKD. Clin J Am Soc Nephro 2013; 8: 1429-48.
- (32) SEO SW, LEE JM, IM K, et al. Cardiovascular Risk Factors Cause Cortical Thinning in Cognitively Impaired Patients Relationships Among Cardiovascular Risk Factors, White Matter Hyperintensities, and Cortical Atrophy. Alz Dis Assoc Dis 2012; 26: 106-12.
- (33) MUNGAS D, JAGUST WJ, REED BR, et al. MRI predictors of cognition in subcortical ischemic vascular disease and Alzheimer's disease. Neurology 2001; 57: 2229-35.
- (34) KURELLA TAMURA M, WADLEY V, YAFFE K, et al. Kidney function and cognitive impairment in US adults: the Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study. American journal of kidney diseases : the official journal of the National Kidney Foundation 2008; 52: 227-34.
- ETGEN T, CHONCHOL M, FORSTL H, SANDER D. Chronic kidney disease and cognitive impairment: a systematic review and meta-analysis.
 American journal of nephrology 2012; 35: 474-82.
- MIWA K, TANAKA M, OKAZAKI S, et al. Chronic kidney disease is associated with dementia independent of cerebral small-vessel disease. Neurology 2014; 82: 1051-7.
- (37) ROMAN GC, ERKINJUNTTI T, WALLIN A, PANTONI L, CHUI HC. Subcortical ischaemic vascular dementia. Lancet neurology 2002; 1: 426-36.
- MOGI M, HORIUCHI M. Clinical Interaction between Brain and Kidney in Small Vessel Disease. Cardiology research and practice 2011; 2011: 306189.
- (39) SEDAGHAT S, VERNOOIJ MW, LOEHRER E, et al. Kidney Function and Cerebral Blood Flow: The Rotterdam Study. Journal of the American Society of Nephrology : JASN 2016; 27: 715-21.
- (40) SEIFTER JL, SAMUELS MA. Uremic Encephalopathy and Other BrainDisorders Associated with Renal Failure. Semin Neurol 2011; 31: 139-43.
- (41) BUGNICOURT JM, GODEFROY O, CHILLON JM, CHOUKROUN G, MASSY ZA. Cognitive disorders and dementia in CKD: the neglected kidney-brain axis.

Journal of the American Society of Nephrology : JASN 2013; 24: 353-63.

- (42) KNOPMAN DS, VEMURI P, JACK C, et al. Alzheimer's and Vascular Disease-specific Structural Brain Changes in Chronic Kidney Disease Patients. Alzheimer's & Dementia: The Journal of the Alzheimer's Association 2014; 10: P498-P9.
- (43) MURRAY AM, KNOPMAN DS, ROSSOM RC, HEUBNER B, TUPPER D, AMIOT E. Cognitive impairment in moderate chronic kidney disease: The Brain in Kidney Disease (BRINK) study. Alzheimer's & Dementia: The Journal of the Alzheimer's Association 2014; 10: P499-P500.
- (44) NEUROPATHOLOGY GROUP. MEDICAL RESEARCH COUNCIL COGNITIVE F, AGING S. Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS). Lancet 2001; 357: 169-75.
- (45) WEN CP, CHENG TY, TSAI MK, et al. All-cause mortality attributable to chronic kidney disease: a prospective cohort study based on 462 293 adults in Taiwan. Lancet 2008; 371: 2173-82.
- (46) HEALTH PROMOTION ADMINISTRATION MOHAWROCT. TAIWAN TOBACCO CONTROL ANNUAL REPORT 2014, 2015.

7. Appendix

Supporting information



Table S1 Multiple linear regression analyses of neuropsychological test scores and brain volume parameters

Predictor	β	Standard	t	p	Lower	Upper
		error			Bound	Bound
Model 1 Neur	opsycholog	gical test scores	5			
Test			N	MSE		
Predictor			LΨ.			
Age	-0.001	0.05	-0.25	0.80	-0.10	0.08
CKD ^a	-2.98	0.73	-4.11	0.00	-4.43	-1.54
Education	0.18	0.07	2.48	0.02	0.04	0.33
		Ver	bal Fluen	cy		
Age	-0.15	0.05	-3.26	0.002	-0.25	-0.06
CKD	1.51	0.74	2.06	0.04	0.04	2.99
Education	0.12	0.08	1.55	0.13	-0.03	0.27
	Digit span forward					
Age	-0.03	0.03	-1.00	0.32	-0.10	0.03
CKD	-1.65	0.53	-3.10	0.003	-2.71	-0.59
Education	0.08	0.06	1.35	0.18	-0.04	0.19
		Digit sp	an backwa	ard		
Age	-0.06	0.03	-1.99	0.05	-0.13	0.00
CKD	-0.50	0.53	-0.94	0.35	-1.56	0.56
Education	0.21	0.06	3.83	0.00	0.10	0.32
Model 2 Brain	structure v	volume				
		,	WMH			
Age	0.40	0.25	1.62	0.11	-0.09	0.90
CKD	5.32	3.99	1.33	0.19	-2.63	13.27
		Gra	y matter			

Age	-994.42	566.34	-1.76	0.08	-2122.63	133.78	
CKD	-26868.31	9066.69	-2.96	0.004	-44930.09	-8806.53	
	White matter volume						
Age	-784.00	713.88	-1.10	0.28	-2206.13	638.13	
CKD	-31897.83	11428.82	-2.79	0.007	-54665.20	-9130.45	
		Нірроса	ampus volu	ıme			
Age	-33.90	11.10	-3.05	0.003	-56.00	-11.79	
CKD	-681.31	177.66	-3.84	0.00	-1035.22	-327.39	
	Total intracranial volume						
Age	1846.17	2311.67	0.80	0.43	-2758.92	6451.25	
CKD	-44870.76	37008.38	-1.21	0.23	-118595.23	28853.71	
Cortical thickness							
Age	-0.005	0.002	-2.66	0.01	-0.01	-0.001	
CKD	-0.09	0.030	-3.13	0.003	-0.15	-0.03	

Note:β=unstandardized beta coefficient, t=test statistics, CKD^a: 0=normal control, 1=CKD, CKD, Chronic kidney disease; MMSE, Mini-Mental State Examination,; WMH, White matter hyperintensity

Table S2 Distribution of decreased cortical thickness in both hemispheres

Left hemisphere	Right hermispehre
G_and_S_transv_frontopol	G_oc-temp_med-Lingual
G_oc-temp_med-Lingual	Lat_Fis-posterior
S_calcarine	S_circular_insula_superior
S_occipital_ant	S_oc_sup_and_transversal
S_temporal_inferior	S_parieto_occipital
S_temporal_superior	S_temporal_superior

G: Gyrus; S: Sulcus. Correct *p* value was set to 0.01 by FDR of 0.05.